Vir Biotechnology (VIR) Total Current Liabilities (2018 - 2026)

Vir Biotechnology (VIR) has 9 years of Total Current Liabilities data on file, last reported at $73.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 46.42% year-over-year to $73.6 million; the trailing twelve-month figure through Mar 2026 stood at $73.6 million (down 46.42% YoY), and the FY2025 full-year result was $92.8 million, down 22.44% from the prior year.
• Total Current Liabilities retreated to $73.6 million in Q1 2026, from $92.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $702.4 million in Q1 2022 to a low of $73.6 million in Q1 2026.
• A 5-year average of $233.1 million and a median of $137.3 million in 2025 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 227.25% in 2022 and plunged 80.62% in 2024, its largest moves.
• Tracing VIR's Total Current Liabilities over 5 years: stood at $511.0 million in 2022, then sank by 65.68% to $175.4 million in 2023, then plunged by 31.78% to $119.7 million in 2024, then dropped by 22.44% to $92.8 million in 2025, then declined by 20.75% to $73.6 million in 2026.
• Business Quant data shows VIR's Total Current Liabilities at $73.6 million in Q1 2026, $92.8 million in Q4 2025, and $75.2 million in Q3 2025.